Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Navigating Treatment Options for CML Across the Disease Continuum: An Expert Case-Based Discussion

Release Date: September 3, 2021
Expiration Date: September 3, 2022

Activity Overview

The treatment landscape of chronic myeloid leukemia (CML) was transformed in 2001, with the approval of imatinib, the first BCR-ABL tyrosine kinase inhibitor (TKI) to be used in the management of this disease. There are currently 5 TKIs approved for the treatment of CML: imatinib, nilotinib, dasatinib, bosutinib, and ponatinib. The main challenges faced by physicians treating patients with CML include how and when to monitor patients for response to therapy, how to treat patients who have a suboptimal response in the second-line setting, and effectively sequencing therapies in the third-line setting. In addition, individualizing TKI selection based on a knowledge of each agent’s unique adverse effect profile, as well as patient medical history and comorbidities, can also be a challenge. Equally important are the management of adverse effects associated with TKI therapy, understanding when a TKI therapy can be discontinued without affecting outcomes, and which parameters to keep in mind for regular monitoring after TKI discontinuation.
The goals of this educational program are to assess the unmet needs in CML management and review emerging agents in both first-line therapy and refractory/relapsed disease. In addition, expert faculty will review the proactive management of adverse events across the CML spectrum of disease and offer advice on shared decision-making aimed at aligning patient goals with clinical advances and guidelines.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with CML. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of CML will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Utilize shared decision-making and monitoring strategies to inform treatment decisions and switching opportunities along the CML disease continuum
  • Summarize data from recent clinical trials evaluating the efficacy and safety of novel therapies to treat patients with CML along the disease continuum
  • Outline strategies to individualize therapy in CML for patients who may require switching based on the risk of relapse, performance status, and treatment-related adverse events
  • Apply best practices for shared decision-making to align patient goals with clinical advances and guidelines in CML therapy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Elias Jabbour, MD
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Pfizer, Spectrum Pharmaceuticals, Takeda.


Hagop M. Kantarjian, MD
Hagop M. Kantarjian, MD
Professor and Chair
Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: AbbVie, Amgen, Ascentage, Bristol Myers Squibb Daiichi Sankyo, ImmunoGen, Jazz, Pfizer, Sanofi; Other Support: Honoraria: AbbVie, Actinium Pharmaceuticals, Adaptive Biotechnologies, Amgen, Aptitude Health, Bio Ascend, Daiichi Sankyo, Delta FlyReady, Janssen Global, Novartis, Oxford Biomedical, Pfizer, Takeda Oncology.

Shilpa Paul, PharmD, BCOP
Shilpa Paul, PharmD, BCOP
Clinical Pharmacy Specialist, Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, TX

Disclosures: Shilpa Paul, PharmD, BCOP has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By